Stenocare A/S
The answer first
Does Stenocare beat the market?
No, Stenocare has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 9% of Nordic stocks
- Quality52
- Value24
- Trend3
No. 165 of 195 in healthcare
Max for seven days
Follow Stenocare with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Stenocare
Your first answer is free, no account needed.
Do you own Stenocare, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Stenocare and a few more. Free, no card.
Super Stock+46.4%In short
- Stenocare has fallen 70.9% over the past year, including dividends.
- Overall, Stenocare ranks better than 9% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 95.3%. The price is 97.1% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 9% of Nordic stocks.
No. 165 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 126 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.09
- Asset turnoverSales divided by everything the company owns1.13
- Return on equityProfit divided by equity−21.8%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 85 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.9
- P/SPrice divided by sales1.8
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 184 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−43.9%
- 6 months−51.8%
- 9 months−61.4%
- 12 months−70.9%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Stenocare
4 funds we follow own Stenocare. The share is how much of the fund the stock makes up.
- Denmark4
From the funds' latest known holdings.
About Stenocare
Stenocare A/S is a company in healthcare, listed on Nasdaq Copenhagen. By market value, Stenocare is number 18 of 20 companies in healthcare on Nasdaq Copenhagen. Stenocare has not paid a dividend in the past twelve months. Of the three measures in the ranking, Stenocare is strongest on quality, better than 52% of Nordic stocks. The share trades in DKK. It has around 4 employees.
Stenocare A/S cultivates, produces, imports, distributes, and sells prescription-based medical cannabis products to patients in Denmark and internationally. It offers medical cannabis oil products, including THC, THC/CBD, and CBD, as well as CBD100 oil products. The company was incorporated in 2017 and is based in Randers, Denmark.


See the full analysis of Stenocare.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card